Session Information
Date: Tuesday, November 10, 2026
Session Type: Poster Session C
Session Time: 10:30AM-12:30PM
Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapy holds great promise for cancer and a growing range of immune-mediated diseases, but responses are not always durable, partly because CAR-T cells become exhausted and lose persistence under chronic antigen stimulation. Several transcription factors are known to enhance CAR-T persistence, but a systematic, unbiased survey has been lacking. We therefore screened all human transcription factors (TFs) in parallel, in vitro and in vivo, to find factors that enhance CAR-T persistence and antitumor efficacy.
Methods: We used the Multiplexed Overexpression of Regulatory Factors (MORF) library (Joung et al., Cell 2023), a barcoded lentiviral library encoding 1,836 human transcription factors (TFs; 3,548 isoform-resolved barcodes) that enables quantification of each TF by next-generation sequencing. The library was transduced into CD19/BCMA dual-targeting (dual-CAR) T cells (MOI 0.3), followed by puromycin selection; the resulting cells were cryopreserved as the Day 0 input. Screening was carried out in parallel, in vitro and in vivo. In vitro, cells were repeatedly stimulated with Nalm6 cells over multiple rounds in the absence of exogenous cytokines. In vivo, the library was adoptively transferred into immunodeficient mice bearing established Nalm6 leukemia, and CAR-T cells were recovered from the bone marrow, spleen, and blood. Hits were defined by significant enrichment relative to the Day 0 input. We prioritized for validation a single TF that scored as a hit in both arms: it was individually overexpressed in CAR-T cells, compared with established persistence-enhancing factors as positive controls, and evaluated for efficacy, persistence, and safety across multiple donors, in vitro and in vivo.
Results: The in vitro and in vivo screens yielded 11 and 12 enriched TFs (adjusted p< 0.01), respectively, with three enriched in both. We focused on one of these - a TF not normally expressed in peripheral T cells and not previously studied in T cells. TF-expressing cells gave better tumor control and reached a higher peak expansion in vivo. After a rechallenge given at four times the initial tumor burden, positive-control cells relapsed within about two weeks, whereas TF-expressing cells maintained tumor control through Day 105, with all mice tumor-free at that point; one mouse relapsed transiently and again cleared the tumor. Upon repeated tumor stimulation in vitro, TF-expressing cells outperformed BFP control cells over repeated rounds and showed a stronger memory phenotype and greater metabolic fitness. Finally, in the absence of cytokine support, the TF did not drive antigen-independent proliferation.
Conclusion: Using an unbiased screen across all human transcription factors, we identified a factor – not previously studied in T cells – that improves CAR-T persistence and antitumor efficacy. The engineered cells controlled tumors through high-dose rechallenge and sustained their function under repeated antigen challenge, without antigen-independent proliferation. This factor may provide a broadly applicable strategy for engineering more durable CAR-T cells across hematologic malignancies, autoimmune disease, and solid tumors.
To cite this abstract in AMA style:
Zhou X, Hu J, Zhou Y, Ti A, Zhou L, Chen T, Feng X, Liu Y, Wang H, Zhang Q, Zhang P, Church G, Yang L. A Genome-Scale, In Vivo Transcription Factor Screen Identifies a Previously Unrecognized Factor That Enhances CAR-T Persistence and Tumor Control Under High-Dose Rechallenge [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/a-genome-scale-in-vivo-transcription-factor-screen-identifies-a-previously-unrecognized-factor-that-enhances-car-t-persistence-and-tumor-control-under-high-dose-rechallenge/. Accessed .ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-genome-scale-in-vivo-transcription-factor-screen-identifies-a-previously-unrecognized-factor-that-enhances-car-t-persistence-and-tumor-control-under-high-dose-rechallenge/
